NGM(Delisted)
Ngm Biopharmaceuticals·NASDAQ
--
--(--)
NGM fundamentals
Ngm Biopharmaceuticals (NGM) released its earnings on May 16, 2019: revenue was -- (YoY 0.00%), beat estimates; EPS was -- (YoY 0.00%), met estimates.
Revenue / YoY
--
0.00%
EPS / YoY
--
0.00%
Report date
May 16, 2019
EPS
Revenue
Revenue & Expenses
NGM has released its 2023 Q4 earnings report, with revenue of 165.00K, reflecting a YoY change of -99.09%, and net profit of -27.67M, showing a YoY change of 24.06%. The Sankey diagram below clearly presents NGM's revenue sources and cost distribution.
Key Indicators
Ngm Biopharmaceuticals (NGM) key financial stats and ratios, covering profitability, financial health, and leverage.
Ngm Biopharmaceuticals (NGM)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Ngm Biopharmaceuticals (NGM)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Ngm Biopharmaceuticals (NGM)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Ngm Biopharmaceuticals (NGM) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Ngm Biopharmaceuticals (NGM) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
No Data
